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D
b / xb2 microglobulin (b2m) null mice transgenic for a chimeric HLA-A2.1/D
b-b2m single chain (HHD mice) are an effective
biological tool to evaluate the antitumour cytotoxic T-lymphocyte response of known major histocompatibility-restricted peptide
tumour-associated antigens, and to screen for putative unknown novel peptides. We utilised HHD lymphocytes to identify
immunodominant epitopes of colon carcinoma overexpressed genes. We screened with HHD-derived lymphocytes over 500
HLA-A2.1-restricted peptides derived from colon carcinoma overexpressed genes. This procedure culminated in the identification of
seven immunogenic peptides, three of these were derived from the ‘human 1-8D gene from interferon inducible gene’ (1-8D). The
1-8D gene was shown to be overexpressed in fresh tumour samples. The three 1-8D peptides were both antigenic and immunogenic
in the HHD mice. The peptides induce cytotoxic T lymphocytes that were able to kill a colon carcinoma cell line HCT/HHD, in vitro
and retard its growth in vivo. One of the peptides shared by all the 1-8 gene family primed efficiently normal human cytotoxic
T lymphocyte precursors. These results highlight the 1-8D gene and its homologues as putative immunodominant tumour-associated
antigens of colon carcinoma.
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Supplementary approaches to surgery and chemotherapy promise
better treatment to metastases. One such approach is specific
active immunotherapy aimed at induction of anti-tumour
cytotoxic T lymphocytes (CTL) (Eisenbach et al, 2000). Upon
appropriate vaccination, CTL constitute powerful effectors against
tumours that present on their cell-surface major histocompatibility
(MHC) class I molecules with bound tumour-associated antigenic
(TAA) peptides (Eisenbach et al, 2000).
Different types of TAA have been identified. Antigens that are
uniquely expressed in tumours (Luftl et al, 2004); antigens derived
from differentiation markers (Panelli et al, 2000); antigens arise
from mutations that are common in tumours (McArdle et al,
2000); antigens from a viral source (Youde et al, 2004); and self-
antigens that are overexpressed in tumours (Bar-Haim et al, 2004).
In the latter category, although strong immune reactions against
this type of antigens might result in the destruction of normal
tissues, experience with peptide immunisation has not demon-
strated high toxicity in humans and animals (Gross et al, 2004).
Thus far, little is known about target antigens for CTL in
colorectal carcinoma. The few potential targets belong to the
family of self overexpressed genes, such as her-2/neu, CEA and
Ep-CAM (Melief et al, 2000). Therefore, there is a strong need to
expand the armoury against colon carcinoma by discovering new
TAAs (Nagorsen et al, 2000). Since the repertoire of peptides
eluted from surface MHC class I molecules is highly similar
between normal colon and colon tumours (Melief et al, 2000), we
focused our efforts to identify novel colon carcinoma TAAs from
colon carcinoma overexpressed genes.
We utilised the data of Zhang et al (1997) comparing transcripts
of colon tumour tissue samples and normal tissues excised from
the same patients. This study yielded a set of 26 overexpressed
genes that are expressed in tumours at least five-fold higher than in
normal tissue.
We used the D
b b2 microglobulin (b2m) null mice, transgenic
for a recombinant HLA-A2.1/D
b-b2m single chain (HHD mice), in
order to identify only immunologically relevant MHC class I-
restricted peptides. These mice mount only HLA-A2.1-restricted
CTL responses and were demonstrated as a useful biological tool
for identifying potential TAA HLA-A2.1-restricted epitopes (Firat
et al, 1999; Carmon et al, 2000; Machlenkin et al, 2005).
We applied the HHD model and showed that from over 500
putative TAA peptides derived from the 26 overexpressed genes in
colon carcinoma, seven peptides were antigenic and immunogenic
in HHD mice. Three of the seven were derived from ‘human 1-8D
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sfrom interferon inducible gene’ (1-8D gene, IFITM2). These peptides
elicit a CTL response against a colon carcinoma cell line in vitro and in
vivo. One of the peptides shared by all members of the 1-8 interferon
inducible gene family was highly immunogenic in human peripheral
blood mononuclear cells (PBMCs). These results highlight 1-8D gene
and its family as a novel colon carcinoma TAA.
MATERIALS AND METHODS
Mice
The derivation of HLA-A2.1/D
b-b2 monochain, transgenic,
H-2D
bxb2m double-knockout mice (named HHD mice) has been
described by Pascolo et al (1997). CD1-nude mice were bred in the
Weizmann Institute of Science (Rehovot, Israel). All protocols
involving animals were in compliance with the Institutional Animal
Care and Use Committee and in accordance with the guidelines of the
Weizmann Institute of Science institutional animal care and use
committee (IACUC). All the experiments, methods and facilities have
been accredited by Ministry of Health: The Council for Experimenta-
tion on Animals, National Institute of Health: Office of Laboratory
Animal Welfare and by Association for Assessment and Accreditation
of Laboratory Animal Care (AAALAC). These accreditations meet the
standards required by the UKCCCR guidelines.
Antibodies
BB7.2 and B9.12 are mouse monoclonal antibodies against HLA-A2
(Pascolo et al, 1997). CTLA-4-Ig fusion was used to detect surface
expression of B7.1.
Cell lines
HCT-15, HCT/HHD and HCT/HHD/B7.1 were maintained in DMEM
containing 10% FCS, combined antibiotics, 2mM glutamine. RMA-S,
RMA-S/HHD/B7.1, T2, EL4/HHD (provided by Dr FA Lemonnier,
Pasteur Institute, Paris, France), EL4/HHD/1-8D-Myc were grown in
RPMI containing 10% FCS, combined antibiotics, 2mM glutamine,
5 10
 5M bME and 50mgml
 1 hygromycin.
Preparation of tumour extract peptides
Total acid-extracted peptides of colon tumour or of normal
adjacent tissues were prepared from a pool of six post-surgical
colon cancer specimens. Non-necrotic (1–2cm) tumour masses
were homogenised in PBS, 0.5% Nonidet P-40, 10mgml
 1 soybean
trypsin inhibitor, 5mgml
 1 leupeptine, 8mgml
 1 aprotonin and
0.5mM PMSF and homogenised using a glass-teflon homogeniser.
Following further stirring for 30min at 41C, the homogenates were
titrated with 10% TFA to a final concentration of 0.1% TFA and
stirred for another 30min at 41C. After ultracentrifugation for
30min at 42Kr.p.m., the supernatants were applied to Sephadex
G25 columns and fractions were monitored at OD 230nm. Peptide
fractions below 10kDa were pooled, lyophilised and further
fractionated by Centripep 3 centrifugation (Amicon, Beverly,
MA, USA). Lyophilised samples were dissolved in sterile double
distilled water, freed from TFA by repeated lyophilisation, and the
relative concentration was assessed by measuring the OD at
230nm. Following lyophilisation, the peptide pool was dissolved in
optiMEM (Life Technologies, Paisley, UK) at 30–50 OD at 230nm
per ml for further use.
Peptide synthesis
Peptides were synthesised on an ABIMED AMS 22 multiple
peptide synthesiser (Abimed, Langenfeld, Germany), employing
Fmoc strategy. Crude peptides were purified to homogeneity
by semipreparative RP-HPLC. For the screening experiments,
peptides were synthesised by multi-parallel synthesis (MPS)
method adapted to 96-well plates, as was developed by Peptor
Ltd (Rehovot, Israel). The peptides were purified by solid-phase
extraction over C-18 Sep-Pak resin and analysed by VG platform,
API-ESI MS (Fisons, UK). The average purity of the MPS peptides
was about 80% as was analysed by RP-HPLC.
Vaccination
HHD mice were immunised i.p. three times at 7-day intervals with
2 10
6 irradiated (5000rad) tumour cells, or irradiated peptide-loaded
RMA-S/HHD/B7.1 transfectants. Spleens were removed on day 10 after
the last immunisation, and splenocytes were restimulated in vitro,e i t h e r
with irradiated tumour cells or with one-third of the lymphocytes
prepulsed with 100mM synthetic peptides in optiMEM (Invitrogen,
Paisley, UK) for 2h at 371Ca n d5 %C O 2. Restimulated lymphocytes
were cultured in RPMI-HEPES medium containing 10% FCS, 2mM
glutamine, combined antibiotics, 1mM sodium pyruvate, 25mM HEPES,
5 10
 5M bME and 1% NEAA for 5 days. Viable cells (effectors) were
separated by Lympholyte-M (Cedarlane, Hornby, ON, Canada) gradient,
resuspended and admixed at different ratios with 5000
35S-methionine-
labelled target cells. Cytolytic assays were carried out as described
previously (Carmon et al, 2000). Extracts of tumour peptides or normal
colon peptides were prepared from a pool of six post-surgical colon
carcinoma specimens as described before (Carmon et al, 2000).
To determine the threshold for immunogenicity of the
individual peptides, we vaccinated two HHD mice with each of
the peptides. CTL preparation was made and a cytolytic assay was
performed using either the peptide itself or the tyrosinase epitope-
loaded target cells as a negative control. We defined the ratio of the
specific lysis between the two targets as the ‘immunogenic score’,
which expressed as percent of the control lysis. The lysis of the
tyrosinase-loaded target cells was between 10–20%. We averaged
the control lysis results of all the assays (total 44 measurements in
triplicates) and defined the threshold as 95% confidence level
above the average. This resulted in an immunogenic score of 125%
(a horizontal line at this level was added to Figure 2A). Thus, each
peptide that yielded an average immunogenic score of two
independent experiments above 125% was rendered immunogenic.
RNA extraction and real-time PCR
Total RNA from human tumour and normal colon tissues was
isolated by TriReagent (Molecular Research Center, Cincinnati,
OH, USA) according to the manufacture’s instructions. Colon
tissues were obtained from Barzilai Medical Center (Ashkelon,
Israel) from colon cancer patients according to the Declaration of
Helsinki Principles. Reverse transcription was performed on 5mg
of total RNA with an oligo (dT) primer using Superscriptt II
(Invitrogen). Relative expression of human 1-8D gene in human
tumour and normal colon tissues was detected using the Roche
LightCycler FastStart DNA Master SYBR Green I (Roche,
Mannheim, Germany). b-Actin gene was used as loading control.
Primers were designed to specifically amplify human 1-8D gene:
forward primer for human 1-8D:5 0-CCTTGACCTGTATTCCA
CT-30, reverse primer for human 1-8D:5 0-GCCATTGTAGAAAA
GCGT-30, these amplify a 102-bp region of the gene. For b-actin,
forward primer was 50-GGCATCCACGAAACTAC-30 and reverse
primer 50-GCTCAGGAGGAGCAAT-30; these amplify a 209-bp
region of the gene. Each reaction was carried out in triplicates in
a total volume of 20ml in glass capillaries containing 5mlo f
cDNA sample, 3mM MgCl2, 0.5mM each primer and 2mlo f
LightCycler – FastStart Reaction Mix SYBR Green I mixed with
LightCycler FastStart Enzyme. The thermocycling programme
consisted of denaturation at 951C for 10min, followed by 35–45
cycles of PCR (951C for 5s, 601C for 7s, 721C for 11s and a single
fluorescence detection point at 851C for human 1-8D and at 871C
for b-actin, with transitions programmed at 201Cs
 1). Melting
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scurves were generated by first heating to 951C, then cooling to
601C for 15s, and finally heating at 0.11Cs
 1 to 951C with
continuous fluorescence acquisition. Programme was followed by a
30s 401C. In each case, product identity was demonstrated by the
presence of a single peak on derivate melting curve plots, using the
LightCycler software (Roche), and a single band of the appropriate
size on gel electrophoresis, which corresponded to the sequence in
the database (accession number: X57351).
Cloning of 1-8D gene
RNA was isolated from colon tumour specimens using TriReagent
(Molecular Research Center). Two micrograms of total RNA was
converted to cDNA using SuperScript II (Invitrogen). 1-8D gene
was amplified by PCR by 50-primer-GGTAAGCTTACCGCCGCTG
GTCACCATGAACC; 30-primer-AGAGCTCGAGGCCTCAATGAT
GCCTCCTGATCTATCG.
The PCR fragment was cloned into pcDNA3.1/Hygro(þ) vector
between HindIII and XhoI restriction sites. Myc tag was added at
the C terminus by eliminating the stop codon. Positive clones were
selected by intracellular staining using Cytofix/Cytoperm Plus kit
(Pharmingen, San Diego, CA, USA) using anti-Myc (9E10) mAb
(Santa Cruz Biotechnologies, Santa Cruz, CA, USA).
Adoptive transfer
CD1-nude mice were challenged in the footpad with 3 10
6 HCT/
HHD cells. Three days later, 10
7 viable restimulated effector cells
were injected i.v. to the tail vein. One thousand units of IL-2 were
injected i.p. twice a day for 7 consecutive days post transfer.
Tumour growth was monitored twice a week by measuring the
diameter of the footpad with calipers. Mice were killed when one of
the tumour diameters reached 10mm.
In vitro priming of human CTL
Leukapheresis products of three healthy donors were obtained
from Barzilai Medical Center according to the Declaration of
Helsinki Principles. Peripheral blood mononuclear cells were
isolated by centrifugation on Ficoll–Plaque Plus gradients
(Amersham, Uppsala, Sweden). The procedure was carried out
according to Thurner et al (1999) with minor modifications.
RESULTS
HCT/HHD and colon carcinoma tumour extracts elicit
cross-reactive CTL responses in HHD mice
Successful screening of antigenic peptides relies upon reproducible
screening procedures. The CTL responses obtained to vaccinations
of the HHD mice with low molecular weight extracts of colon
tumours varied from preparation to preparation (data not shown).
Therefore, we decided to vaccinate HHD mice with a cellular
preparation. After screening several colon carcinoma cell lines, we
found that the HCT-15 cell line does not express any HLA class I
molecules and therefore may serve as a convenient platform for
introduction of the single-chain HHD (Figure 1A, lower left panel).
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Figure 1 (A) HCT/HHD/B7.1 cells highly express HHD and B7.1. Cells were stained with B9.12 or CTLA-4-Ig fusion protein and analysed by flow
cytometry. (B) HLA-A2.1-restricted and colon-associated lysis induced by the colon carcinoma HCT/HHD transfectant. Mice were immunised with HCT/
HHD/B7.1 cells. (a) Lysis of RMA-S/HHD loaded with colon-derived TE, NE and non-relevant peptides (b) as well as the transfectant itself and the parental
cell line were monitored by CTL assays. The specific lysis at a 50:1 effector to target ratio is shown. (C) Colon carcinoma-associated CTL responses
in patient-derived TE-immunised mice. CTL assays utilising anti-patient-derived TE-activated lymphocytes were performed. Colon cell line HCT/HHD or
non-relevant tyrosinase synthetic peptides as well as tumour- and normal-derived peptide extract loaded on RMA-S/HHD served as targets (NE). The 25:1
effector to target ratio is shown.
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sWe established HCT-15 cells that highly express the HHD and
murine B7.1 (Figure 1A, upper panels) as potent inducers of CTL
responses in HHD mice (Figure 1B, panel b). We tested the ability
of CTL raised against HCT/HHD/B7.1 cells to identify antigens
extracted from a pool of six colon tumour specimens (tumour
extract (TE)). HHD mice were vaccinated with irradiated HCT/
HHD/B7.1 cells, spleens were removed and cytolytic activity was
assayed on several targets (Figure 1B). We performed a reciprocal
experiment, in which HHD mice were vaccinated with RMA-S/
HHD/B7.1 loaded with the colon-derived TE and cytolytic activity
was measured on the indicated targets (Figure 1C). HCT/HHD/
B7.1 elicits a powerful CTL response against itself in an HHD-
restricted manner (compare HCT/HHD vs HCT). The CTL
preferentially identified TE loaded on target cells but not cells
loaded with either normal extract (NE) (prepared from a pool of
normal colon), or tyrosinase-derived peptide, as a negative control
(Figure 1B, panel a). When RMA-S/HHD/B7.1 cells loaded with TE
were used to induce a CTL response, HCT was lysed in an HHD-
restricted manner. The response mounted against NE and
tyrosinase was approximately 20% lower than the response against
TE (Figure 1C, Po0.05). These experiments demonstrate a
significant overlap between HCT antigens and antigens extracted
from colon carcinoma tumour specimens. Thus, establishing
vaccination with HCT/HHD/B7.1 as an immunological model for
human colon carcinoma.
Twenty-two peptides are antigenic to anti-HCT/HHD/B7.1
effector cells
We focused on putative non-secreted 26 genes (Table 1),
previously reported to be overexpressed at least five-fold in colon
tumour tissues (Zhang et al, 1997). The protein sequences were
screened for putative HLA-A2.1-restricted peptides using the
‘independent binding of individual peptide side-chains’ software
(Parker et al, 1994). We selected high-and medium-affinity HLA-
A2.1-restricted peptides (score over 1). Overall, 503 peptides were
synthesised by the MPS synthesis technology and loaded on
35S-labelled RMA-S/HHD/B7.1 to serve as targets for CTL. Splenocytes
of HCT/HHD/B7.1-immunised animals were incubated with the
target cells in a 50:1 effector to target ratio. Targets that were
specifically lysed by more than 10% than the negative control in
two consecutive experiments were regarded a positive hit. A list of
the antigenic peptides and their position in the protein of their
origin is shown in Table 2.
Seven peptides derived from overexpressed genes are
immunogenic in HHD mice
Next, the antigenic peptides were tested for their specific immuno-
genicity in HHD mice. HHD mice were immunised with RMA-
S/HHD/B7.1 cells loaded with the individual peptides. A cytolytic
assay was performed on the peptide itself loaded on labelled
RMA-S/HHD or tyrosinase peptide, and the immunogenic score
was determined. These experiments were repeated and the average
score obtained for each peptide is shown in Figure 2A. Threshold
was set as explained in Materials and Methods. According to this
criterion, seven peptides showed significant immunogenicity in the
HHD mice. Three out of the seven peptides, 1–6, 3–5 and 3–7,
Table 1 Colorectal-associated genes
Gene no. Gene name
No. of HLA-A2.1
peptides
1 Human defensin 6 11
2 Human ADP/ATP translocase 24
3 Human parathymosin 1
4 Human 1-8U gene from interferon
inducible gene
25
5 Human chaperonin-like protein 29
6 Human SPARC/osteonectin 23
7 Human 1-8D gene from interferon
inducible gene
24
8 Human TB2 gene 29
9 Human alpha-1 collagen 12
10 Human mRNA for dipeptidase 19
11 Fibronectin 38
12 Actin binding protein 39
13 HCG IV mRNA 19
14 HLA-DR antigens associated invariant
gamma chain
19
15 MHC class I HLA-C.1 gene 29
16 polyA binding protein 29
17 Transforming growth factor-b induced
gene
19
18 H. sapiens mRNA for laminin-binding
protein
18
19 Human mRNA sequence 14
20 Insulin like growth factor II 19
21 Human ribosomal protein L23a mRNA 5
22 Human acidic ribosomal
phosphoprotein P1
8
23 Human liver mRNA fragment DNA
binding protein UPI
5
24 Ribosomal protein L37 1
25 Human MHC protein homologous to
chicken
B complex
29
26 HB23 gene for B23 nucleophosmin 15
The genes were selected according to the following rules: (1) candidate genes with
secretion sequences were excluded; (2) candidate gene must be overexpressed in
tumours at least five-fold higher than in normal tissue. HLA-A2.1-restricted peptides
from the selected genes were selected according to their consensus binding motifs.
Table 2 List of antigenic HLA-A2.1-restricted peptides, their respective
gene and position
Peptide serial no. Name of gene Position
1-1 VLYDELKKV Human ADP/ATP translocase 253–261
1-2 LLVIIPVLV Human 1-8D gene from interferon
inducible gene
119–127
1-3 VQPQSPVAV Actin binding protein 10–18
1-4 FELAAESDV Transforming growth factor b
induced gene
380–388
1-5 GQQSTVSDV Actin binding protein 1415–1423
1-6 EMLKEEQEV Human 1-8D gene from interferon
inducible gene
20–28
1-7 IQQYGHQEV Actin binding protein 657–665
1-8 ALRGHSHFV Human MHC protein homologous
to chicken B complex
58–66
1-9 VIATNILLV Human chaperonin-like protein 368–346
1-10 TILTAVLLV Human defensin 6 5–13
1-11 IVDDITYNV Actin binding protein 492–500
1-12 TLQLSRAPV Human mRNA for dipeptidase 223–231
2-1 ALPDETEVV Human osteonectin 23–31
2-2 IPMGKSMLV Insulin like growth factor II 3–11
2-3 KIEDNNTLV Human ribosomal protein L23a mRNA 89–97
3-1 MLTINGKAI Transforming growth factor b induced
gene
343–351
3-2 SIAEFFSDI Human TB2 gene 105–113
3-3 ALGFYPAEI Human thyroid hormone binding
protein (p55)
229–237
3-4 WVVYGVFSI Human TB2 gene 98–106
3-5 LILGIFMTI Human 1-8D gene from interferon
inducible gene
110–118
3-6 DLQETLVKI Human chaperonin like protein 316–324
3-7 KCLNIWALI Human 1-8D and 1-8U genes from
interferon inducible genes
103–111
The 1-8D-derived peptides are bold and underlined.
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swhich showed the highest immunogenicity, were derived from
‘human 1-8D gene from interferon inducible gene’ (1-8D).
The peptides of ‘1-8D gene’ induce anti-HCT/HHD CTL
responses
Intrigued by this finding, we decided to focus on the 1-8D peptides.
U s i n ga nH L A - A 2s t a b i l i s a t i o na s s a yo nT 2c e l l s( F i r a tet al, 1999), we
verified the binding of the 1-8D peptides to HLA-A2.1 (Figure 2B),
the 1-8D peptides bind to HLA-A2.1, although to a lower extent than
for the tyrosinase peptide, a strong HLA-A2.1 binder.
We next tested 1-8D peptides for induction of anti-HCT/HHD
CTL responses. HHD mice were vaccinated with the 1-8D peptides
as previously described (Carmon et al, 2000). As a negative
control, we used an HIV-derived peptide, TLNAWVKVV. 1-8D
peptides mount more than twice higher CTL responses than the
HIV peptide at a 50:1 effector to target ratio (Figure 2C). We
conclude that 1-8D peptide elicits anti-HCT CTL responses.
The 1-8D gene is overexpressed in primary colon tumour
The relative expression of the human 1-8D gene in colon tumour
tissues vs normal tissues was measured by real-time PCR. An
internal standard curve was generated by amplification of four-
fold dilution of cDNA for each gene in each run. Based on the cycle
number, when the fluorescence detected increased over the noise
or base line (crossing point), the linear regression curve was
calculated. The correlation coefficient r was  1.00, the error was as
well minimal, and the slope near to  3.33. Expression level of
b-actin was used for normalisation. Results are expressed as
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Figure 2 (A) Seven peptides are immunogenic. Peptides were loaded on RMA-S/HHD/B7.1, washed and irradiated. For each peptide, two HHD mice
were immunised three times as described in Materials and Methods. In vitro cytolytic assays were performed on the relevant peptide as target and on an
irrelevant peptide, and the immunogenic score was calculated. The positive peptides (above 125%) are marked by arrows. Peptides 1–6, 3–5 and 3–7 are
derived from ‘human 1-8D gene’. (B) 1-8D peptides stabilise HLA-A2 on T2 cells. T2 cells were acid stripped and incubated overnight with the indicated
peptide and recombinant b2 or with b2m alone as a negative control. Cells were stained with BB7.2 mAb and analysed by flow cytometry. The number of
positive cells above control level is indicated for each of the peptides. (C) 1-8D peptides can mount anti-HCT/HHD CTL responses. HHD mice were
immunised with HCT/HHD/B7.1 and with peptides loaded on RMA-S/HHD/B7.1. In vitro cytolytic assays were performed using HCT/HHD cells as targets.
The specific lysis at a 50:1 effector to target ratio of a representative experiment out of three is shown.
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Figure 3 The 1-8D gene is overexpressed in tumour colon tissues. The
relative expression of human 1-8D gene in tumour and normal colon tissue
was determined using real-time PCR. Expression level of b-actin was
considered equal in both normal and tumour samples and was used for
normalisation while calculating the expression level of the 1-8D gene.
Average±s.d. is presented.
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overexpressed in 9 samples out of 13 that were tested (Figure 3).
These findings indicate that the human 1-8D gene is a bona fide
overexpressed gene in tumour colon tissues.
1-8D peptides are presented on EL4/HHD/1-8D-Myc
To demonstrate that the 1-8D protein is processed and the
peptides are presented, we cloned the 1-8D-Myc into a pcDNA3.1.
vector. Stable EL4/HHD/1-8D cells were generated. HHD mice
were immunised with the 1-8D peptides and a cytolytic assay was
performed using EL4/HHD/1-8D transfectant and the parental
EL4/HHD cells as targets. The 1-8D transfectant was lysed better
than the parental cells when 1–6 and 3–7 restricted CTL were used
(Figure 4A, upper and lower panels). CTL restricted to 3–5 show
minor selectivity towards the 1-8D transfectant (Figure 4A, middle
panel). We conclude that 1-8D is processed, and peptides 1–6 and
3–7 are presented at the cell surface. These results do not confirm
or disprove presentation of 3–5.
Adoptively transferred anti-1-8D peptide lymphocytes
inhibit the growth of HCT/HHD in nude mice
To check whether activation of lymphocytes induced by the 1-8D
peptides harbours an immunotherapeutic potential, HCT/HHD
cells were inoculated to the footpad of nude mice. Three days post
footpad inoculation, restimulated HHD lymphocytes were trans-
ferred i.v. Transfer of anti-1-8D peptide CTL caused significant
retardation in tumour growth. Retardation was detected for
peptide 3–5 starting from day 11 (Po0.05), and for peptides
1–6 and 3–7 starting from day 13 (Po0.05) applying one-tail
Student’s t-test (Figure 4B).
Peptide 3–7 activates peripheral CTL precursors in normal
human PBMCs
Finally, we checked peripheral blood of three healthy individuals
for the presence of CTL precursors (CTLp). Peptide 3–7 primed
effectively CTL in lymphocytes from donors A and B and to a
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Figure 4 (A) 1-8D peptides mount CTL responses that lyse 1-8D transfectants. Each peptide was loaded on RMA-S/HHD/B7.1 and used to immunise
HHD mice. In vitro cytolytic assays were performed using EL4/HHD cells (open circles) and EL4/HHD/1-8D-transfected cells (dark circles) as a target. The
specific lysis of a representative experiment out of three is shown. (B) HCT/HHD growth is inhibited by vaccination with 1-8D peptides. Nude mice were
challenged in the footpad with HCT/HHD cells. Lymphocytes from vaccinated HHD mice were transferred together with IL-2 to the tumour-bearing mice
and the growth of the tumour was monitored twice a week. Statistical significance was achieved for peptides 1–6 and 3–7 from day 13 and for 3–5
treatment from day 11 (Student’s t-test, Po0.05). (C) 1-8D peptide primes in vitro normal CTLp. Peripheral blood mononuclear cells of three leukapheresis
samples were isolated and in vitro priming was performed with peptide-pulsed autologus DC. Peripheral blood mononuclear cells were supplemented with
IL-7, and 2 days later IL-2 was added and renewed every 3 days. The rest of the stimulations were performed every 7 days over peptide-pulsed monocytes.
Seven days after the third stimulation, lymphocytes were harvested and a cytolytic assay was performed using peptide-pulsed or non-pulsed T2 cells as
targets. ’, CTLp from donor A; K, CTLp from donor B; n, CTLp from donor C; and J, non-pulsed T2 cells.
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CTL in lymphocytes of donor B alone and peptide 3–5 primed
CTL in lymphocytes of donors B and C. Unfortunately due to
paucity of PBMCs of donor A, this was not tested with peptide 3–5
(Figure 4C).
DISCUSSION
One approach to identify human tumour-associated HLA class I-
restricted peptides utilises CTL lines derived from patients
(Heidecker et al, 2000). This approach suffers from several caveats:
establishment of CTL lines is a complicated procedure; CTL lines
derived from cancer patients may represent the repertoire of an
anergised immune system; finally, propagation of CTL lines in
vitro might reflect sporadic clones surviving culture conditions
rather than authentic antitumour clones. In order to bypass these
pitfalls and to obtain pure HLA-A2-restricted CTL responses, we
used the HHD mice (Pascolo et al, 1997). We combined a reverse
immunology approach together with a screening procedure that
utilises HHD lymphocytes to identify immunodominant epitopes
of colon carcinoma-overexpressed genes.
The HCT-15 cell line that possess high-tumorigenic properties
was modified to be a suitable antigen-presenting cell by
transfection with the single-chain HHD and the costimulatory
B7.1 molecule (Cayeux et al, 1997) (Figure 1A). These cells were
used to immunise HHD mice, as a source of CTL for epitope
screening. It was important to demonstrate that HCT/HHD/B7.1
elicits a CTL response that overlaps the response obtained with TE
to ensure physiological significance of the screen (Figure 1B).
We found that HCT/HHD/B7.1 elicits strong anti-self, HHD-
restricted CTL response that recognises preferentially the TE
(Figure 1B). Furthermore, CTL of mice, immunised with RMA-S/
HHD/B7.1 cell-loaded TE, show high-specific lysis (over 60%) of
HCT/HHD. The lysis was five-fold higher than of parental cells.
These results suggest that processing and presentation of HLA-
A2.1-restricted and colon-associated peptides are performed by the
HCT/HHD colon carcinoma cells. Likewise, the high-specific lysis
of HCT/HHD transfectants indicates an overlapping peptide
repertoire between the TEs and the cell line.
Two-fold preferential lysis of colon-derived tumour peptide- vs
normal tissue peptide-loaded targets was observed upon vaccina-
tion with colon TE peptides. This observation supports the
existence of a window of specificity, towards which tumour
immunotherapy can be directed.
We selected 26 genes of putative non-secreted proteins that are
expressed at least five-fold higher in tumours than in normal colon
(Table 1). These genes were analysed for HLA-A2.1-restricted
peptides. We screened over 500 HLA-A2.1-restricted peptides and
we found that in a cytolytic assay lymphocytes recognised 22
peptides, rendering them antigenic to the lymphocytes.
Next, we narrowed down the antigenic peptides to those that are
also immunogenic. HHD mice were vaccinated with each of the
individual peptides, and lymphocytes were assayed for lysing
target cells, loaded with either the peptide itself or an irrelevant
peptide. Interestingly, only seven peptides could mount a
significant CTL response in HHD mice (Figure 2A). Three of the
seven were derived from the 1-8 family of interferon inducible
proteins, highlighting these gene products as novel TAA. Binding
of the peptides to HLA-A2 was confirmed by performing a
stabilisation assay on T2 cells (Figure 2B).
The 1-8 gene family is inducible by both type I and type II
interferons (Lewin et al, 1991). Three members of the family: 1-8D,
1-8U and 9-27 (also called IFITM2, IFITM3 and IFITM1,
respectively) are linked on an 18-kb fragment of chromosome 11
and are highly homologous (Lewin et al, 1991). The 9-27 was
shown to be an integral membrane protein identical to the Leu-13
antigen. It forms a complex with other proteins and is implicated
in cell adhesion and growth inhibitory signals (Deblandre et al,
1995). The 1-8U is expressed in colitis-associated colon cancer and
in severely inflamed mucosa in ulcerative colitis (Hisamatsu et al,
1999), as well as in an androgen-independent variant of the
prostate carcinoma line LNCaP, but not in an androgen-dependent
variant (Vaarala et al, 2000). Interestingly, 1-8D and 9-27 are
induced by radiation in a p53-negative line, in an interferon-
independent mechanism (Clave et al, 1997). The expression of 1-8
gene family is induced in a human adrenocortical carcinoma cell
line in response to angiotensin II treatment, implicating other
signalling pathways to control their expression (Daido et al, 2001).
Moreover, it has been demonstrated that IFITM1 activity is
required for primordial germ cell (PGC) transient from the
mesoderm into the endoderm and that IFITM3 is sufficient to
confer autonomous PGC-like homing properties to somatic cells
(Tanaka et al, 2005).
Mouse 1-8 genes termed fragilis/mil have been implicated in the
acquisition of germ cell competence and specification (Barlow
et al, 1984; Saitou et al, 2002; Lange et al, 2003). Sequence
similarity of human, murine and rat 1-8D genes is high (68%). The
homology between human 1-8D and the murine 1-8D proteins
(m1-8D, accession number: BC010291) is 78%. The epitopes
identified from the human 1-8D protein (1–6, 3–5 and 3–7
peptides) are highly similar to the corresponding peptides in m1-
8D protein: human and murine 1–6 (EMLKEEQEV vs ERI-
KEEYEV), human and murine 3–5 (LILGIFMTI vs LVLSILMVV),
and human and murine 3–7 (KCLNIWALI vs KCLNISTLV),
respectively.
We further characterised the 1-8D peptides as potential antigens
for vaccination against colon cancer. Curiously, peptide 3–7, the
most immunogenic peptide in HHD mice harbours a cysteine
residue in its sequence. Moreover, the cysteine residue is situated
at the anchor position of HLA-A2.1 restriction pattern, which
shows preference to aliphatic amino acids like leucine. In
congruent to the study of Chen et al (1999), mutation of the
cysteine to leucine enhanced the immunogenicity of the peptide
albeit not affecting the binding to HLA-A2.1 (data not shown).
An anti-HCT/HHD CTL response was obtained upon vaccina-
tion of HHD mice with either of 1-8D peptides with respect to the
HIV-derived peptide (Figure 2C). The recognition of HCT/HHD by
anti-1-8D lymphocytes further supports the hypothesis of 1-8D
immunodominance in this model.
We elaborated our analysis to tumour specimens and found 1-
8D to be overexpressed in 9 out of 13 fresh tumour samples as
compared to adjacent normal tissue using real-time PCR (Figure 3).
These results establish 1-8D as a bone fide overexpressed gene in
colon cancer.
EL4/HHD cells were transfected with 1-8D. HHD mice were
vaccinated with either of the 1-8D-derived peptides and the
susceptibility of EL4/HHD and EL4/HHD/1-8D cells for lysis by the
active lymphocytes was measured. Despite the high background,
the 1-8D transfectant was better lysed than EL4/HHD cells, by CTL
restricted to peptides 1–6 and 3–7, while peptide 3–5 did not
show 1-8D preference. This fact indicates successful processing
and presentation of 1–6 and 3–7. Presentation of 3–5 was not
confirmed by this assay (Figure 4A). Mixing the anti-1-8D peptide
lymphocytes prior to incubation with the targets did not improved
the lysis of the target cells, but rather resulted in an average lysis
(data not shown). This observation suggests that the three peptides
are derived from a single protein, and presented on MHC class I at
similar levels.
We further examined whether activation of lymphocytes
induced by the 1-8D peptides harbours an immunotherapeutic
potential. We established an adoptive transfer model in which CTL
to 1-8D peptides retarded the growth of HCT/HHD (Figure 4B). In
this experiment, peptide 3–7 was found to be the least effective,
although statistical significance between the various 1-8D peptides
was not achieved. Nonetheless, this result is in concordance with
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3–5 as the most effective vaccine against HCT/HHD (Figure 2C).
Owing to the strong genetic and familial aetiology of colon
cancer, this cancer is appropriate to prophylactic treatment
(Severin, 1999; Lindblom, 2001). Hence, we were interested to
assess the potential of 1-8D peptides to prime peripheral CTL of
normal HLA-A2.1-positive donors. Peripheral blood mononuclear
cells of three normal donors were isolated and assayed for the
existence of CTLp by in vitro stimulations with autologus DCs.
Peptide 3–7 was found to be highly efficient in activating
peripheral CTLp to lyse target cells in a peptide-specific manner
for donors A and B and to a lesser extent for donor C. Peptide 1–6,
however, primed CTL in donor B alone and peptide 3–5 primed
CTL in donors B and C, yet with less efficiency than peptide 3–7
(Figure 4C). This might reflect specific gaps in the T-cell repertoire
in the donors’ peripheral blood that might result from expression
of additional HLA alleles. CTL precursors for all peptides were
found in the peripheral blood of donor B, indicating no tolerance
to peptides 1–6 and 3–5 (Figure 4C). Peptide 3–7 is shared
between the three members of the 1-8 gene family, while the other
peptides (1–6 and 3–5) are unique for the 1-8D gene. The high
immunogenicity of peptide 3–7 in the peripheral blood might be
influenced from the contribution from the three distinct genes, as
opposed to the two other peptides that derive from a single gene.
Additional experiments with PBMCs of different donors are
needed to account for immunogenicity of the 1-8D peptides in
human.
Our study unravels for the first time immunodominant CTL
epitopes of the 1-8D gene family. Based on the interferon
regulation of these genes, and the tight connection of colon
carcinogenesis to inflammation (Lewin et al, 1991), we propose the
1-8D genes as potential targets for a CTL-mediated immunother-
apy of colon carcinoma.
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